Alpha Tau Medical Ltd. (NASDAQ:DRTS) Given Average Rating of “Hold” by Brokerages

Shares of Alpha Tau Medical Ltd. (NASDAQ:DRTS) have received an average recommendation of “Hold” from the six research firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $11.50.

DRTS has been the subject of several analyst reports. Piper Sandler upped their target price on shares of Alpha Tau Medical from $5.00 to $8.00 and gave the company a “neutral” rating in a research note on Tuesday, May 19th. Zacks Research upgraded shares of Alpha Tau Medical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Monday, April 20th. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Alpha Tau Medical in a research note on Wednesday, May 20th. Finally, LADENBURG THALM/SH SH upped their target price on shares of Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Daytona Street Capital LLC bought a new position in Alpha Tau Medical during the 4th quarter valued at $749,000. Apella Capital LLC bought a new position in Alpha Tau Medical during the 4th quarter valued at $1,892,000. Levin Capital Strategies L.P. boosted its stake in Alpha Tau Medical by 6.3% during the 3rd quarter. Levin Capital Strategies L.P. now owns 204,714 shares of the company’s stock valued at $923,000 after acquiring an additional 12,200 shares during the last quarter. Millennium Management LLC boosted its stake in Alpha Tau Medical by 185.7% during the 4th quarter. Millennium Management LLC now owns 107,815 shares of the company’s stock valued at $534,000 after acquiring an additional 70,081 shares during the last quarter. Finally, Mariner LLC boosted its stake in Alpha Tau Medical by 1.6% during the 4th quarter. Mariner LLC now owns 125,165 shares of the company’s stock valued at $620,000 after acquiring an additional 1,915 shares during the last quarter. 2.65% of the stock is currently owned by institutional investors.

Key Alpha Tau Medical News

Here are the key news stories impacting Alpha Tau Medical this week:

• Positive Sentiment: HC Wainwright kept a Buy rating on Alpha Tau Medical and maintained a $15.00 price objective, implying meaningful upside from current levels.
• Neutral Sentiment: The firm’s latest estimates still point to ongoing losses, with multiple quarters projected at -$0.14 EPS and FY2027 EPS at -$0.55, but these figures were broadly in line with the existing subscale profitability outlook.
• Negative Sentiment: HC Wainwright lowered earnings estimates for Q2 2026, Q3 2026, Q4 2026, and FY2026, signaling a weaker near-term profit outlook for Alpha Tau Medical.

Alpha Tau Medical Price Performance

DRTS opened at $10.04 on Monday. The company has a quick ratio of 7.45, a current ratio of 7.79 and a debt-to-equity ratio of 0.09. Alpha Tau Medical has a 52-week low of $2.81 and a 52-week high of $11.62. The company has a 50 day moving average of $8.02 and a two-hundred day moving average of $6.57. The company has a market cap of $883.62 million, a P/E ratio of -14.99 and a beta of 1.11.

Alpha Tau Medical (NASDAQ:DRTS) last released its quarterly earnings data on Monday, May 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). On average, analysts expect that Alpha Tau Medical will post -0.6 earnings per share for the current year.

Alpha Tau Medical Company Profile

Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.

The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.